In summary, whilst there is evidence for a direct relationship between KRAS mutations and YAP activation in colon, pancreatic and lung cancer, this is not the case in (rhabdo-myoblasts) as KRAS G12V and YAP1 S127A drive mostly different gene expression programmes and that KRAS G12V expression alone or in combination of other genetic variations does not activate Yap/Taz in myoblasts. Here, KRAS is linked to lung carcinoma.